Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III RB0026 for RSV prevention in preterm and term infants in China
ChiCTR2600123076Phase 3Completed
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing RB0026 injection with Placebo (2 arms). Primary endpoint: Incidence of medically attended RSV lower respiratory tract infections (MALRTI) within 150 days. Started Apr 2026; status: completed.
02
Drugs
RB0026
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on ChiCTR2600123076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123076.